Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2010 ASCO Annual Meeting

4 - 8 Jun 2010
Netherlands
Sarah Cannon Research Institute research developments at ASCO 2010
Dr Howard Burris, The Sarah Cannon Research Institute, Nashville
Sarah Cannon Research Institute research developments at ASCO 2010 ( Dr Howard Burris, The Sarah Cannon Research Institute, Nashville )
4 Feb 2011
The TOPICAL trial
Dr Siow Ming Lee, University College London, UK
The TOPICAL trial ( Dr Siow Ming Lee, University College London, UK )
3 Aug 2010
Optimising adjuvant therapy in the treatment of early stage endometrial cancer p...
Dr Carien Creutzberg - Leiden University Medical Center, Netherlands
Optimising adjuvant therapy in the treatment of early stage endometrial cancer patients ( Dr Carien Creutzberg - Leiden University Medical Center, Netherlands )
2 Aug 2010
Targeted therapy for bone metastases
Professor Robert Coleman, Weston Park Hospital, Sheffield, UK
Targeted therapy for bone metastases ( Professor Robert Coleman, Weston Park Hospital, Sheffield, UK )
23 Jul 2010
Factors influencing the choice of bone metastases treatment
Professor Robert Coleman, Weston Park Hospital, Sheffield, UK
Factors influencing the choice of bone metastases treatment ( Professor Robert Coleman, Weston Park Hospital, Sheffield, UK )
23 Jul 2010
Costs and benefits of bone metastases therapies
Professor Robert Coleman, Weston Park Hospital, Sheffield, UK
Costs and benefits of bone metastases therapies ( Professor Robert Coleman, Weston Park Hospital, Sheffield, UK )
23 Jul 2010
Early diagnosis of amyloidosis
Dr Giampaolo Merlini - University of Pavia, Italy
Early diagnosis of amyloidosis ( Dr Giampaolo Merlini - University of Pavia, Italy )
22 Jul 2010
The launch of Sarah Cannon Research UK and research developments at ASCO 2010
Dr Jeffrey Infante - Sarah Cannon Research Institute, USA
The launch of Sarah Cannon Research UK and research developments at ASCO 2010 ( Dr Jeffrey Infante - Sarah Cannon Research Institute, USA )
22 Jul 2010
Key advances in ovarian cancer from ASCO 2010
Dr Prof Jonathan Ledermann - UCL Cancer Institute, UK
Key advances in ovarian cancer from ASCO 2010 ( Dr Prof Jonathan Ledermann - UCL Cancer Institute, UK )
22 Jul 2010
Systemic therapy - what lies ahead?
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
Systemic therapy - what lies ahead? ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
20 Jul 2010
Ovarian cancer research
Professor Stan Kaye - Institute of Cancer Research, London, UK
Ovarian cancer research ( Professor Stan Kaye - Institute of Cancer Research, London, UK )
20 Jul 2010
Prognostic and predictive markers in breast cancer
Dr Christoph Thomssen - Martin-Luther University, Halle, Germany
Prognostic and predictive markers in breast cancer ( Dr Christoph Thomssen - Martin-Luther University, Halle, Germany )
20 Jul 2010
Targeted therapy in sarcoma treatment
Prof Gary Schwartz -Memorial Sloan-Kettering Cancer Center, New York, USA
Targeted therapy in sarcoma treatment ( Prof Gary Schwartz -Memorial Sloan-Kettering Cancer Center, New York, USA )
20 Jul 2010
ALK mutation related non-small cell lung cancer
Prof George Demetri - Harvard Medical School, USA
ALK mutation related non-small cell lung cancer ( Prof George Demetri - Harvard Medical School, USA )
20 Jul 2010
The PRIMA study
Prof Gilles Salles - Universite Claude Bernard Lyon, France
The PRIMA study ( Prof Gilles Salles - Universite Claude Bernard Lyon, France )
20 Jul 2010
An immunotherapy approach to pancreatic cancer
Dr Gregory Beatty - University of Pennsylvania, USA
An immunotherapy approach to pancreatic cancer ( Dr Gregory Beatty - University of Pennsylvania, USA )
20 Jul 2010
Biotherapy Development Association
Prof Heinz Zwierzina - Innsbruck Medical University, Austria
Biotherapy Development Association ( Prof Heinz Zwierzina - Innsbruck Medical University, Austria )
20 Jul 2010
PARP inhibitors
Professor Hilary Calvert - University College London, UK
PARP inhibitors ( Professor Hilary Calvert - University College London, UK )
20 Jul 2010
Advances in melanoma treatment
Prof John Wagstaff - University of Swansea, Wales
Advances in melanoma treatment ( Prof John Wagstaff - University of Swansea, Wales )
20 Jul 2010
Potential biologic causes of the racial survival disparity seen in breast cancer
Prof Kathy Albain - Loyola University Chicago, USA
Potential biologic causes of the racial survival disparity seen in breast cancer ( Prof Kathy Albain - Loyola University Chicago, USA )
20 Jul 2010
Advances in the treatment of melanoma
Prof Alexander Eggermont - Erasmus University of Rotterdam, Netherlands
Advances in the treatment of melanoma ( Prof Alexander Eggermont - Erasmus University of Rotterdam, Netherlands )
20 Jul 2010
The role of radiotherapy in the treatment of locally advanced prostate cancer
Prof Malcolm Mason - Cardiff University, Wales
The role of radiotherapy in the treatment of locally advanced prostate cancer ( Prof Malcolm Mason - Cardiff University, Wales )
20 Jul 2010
Drug developments presented at ASCO 2010
Dr Silvia Marsoni - Mario Negri Institute, Milan, Italy and Prof Filippo de Brau...
Drug developments presented at ASCO 2010 ( Dr Silvia Marsoni - Mario Negri Institute, Milan, Italy and Prof Filippo de Braud - European Institute of Oncology, Milan, Italy )
20 Jul 2010
Geriatric oncology
Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland
Geriatric oncology ( Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland )
20 Jul 2010
Phase III clinical trials at ASCO 2010
Prof Patrick Schöffski - Catholic University Leuven, Belgium
Phase III clinical trials at ASCO 2010 ( Prof Patrick Schöffski - Catholic University Leuven, Belgium )
20 Jul 2010
The ASCO/ECCO joint symposium
Prof Michael Baumann - University of Technology, Dresden, Germany
The ASCO/ECCO joint symposium ( Prof Michael Baumann - University of Technology, Dresden, Germany )
20 Jul 2010
Breast cancer research from ASCO 2010
Dr Susanne Briest - University of Leipzig, Germany
Breast cancer research from ASCO 2010 ( Dr Susanne Briest - University of Leipzig, Germany )
20 Jul 2010
The impact of radiotherapy on patients with high risk localised prostate cancer
Prof Wendy Parulekar - Queen's University, Canada
The impact of radiotherapy on patients with high risk localised prostate cancer ( Prof Wendy Parulekar - Queen's University, Canada )
20 Jul 2010
Views on the joint ASCO-ASH education session
Dr Elisabeth Pitterman - Hanusch Hospital, Vienna, Austria
Views on the joint ASCO-ASH education session ( Dr Elisabeth Pitterman - Hanusch Hospital, Vienna, Austria )
15 Jul 2010
Views on the joint ASCO-ASH education session
Dr Elisabeth Pitterman - Hanusch Hospital, Vienna, Austria
Views on the joint ASCO-ASH education session ( Dr Elisabeth Pitterman - Hanusch Hospital, Vienna, Austria )
15 Jul 2010
The efficacy of denosumab and zoledronic acid as treatment for prostate cancer
Dr Karim Fizazi - Institut Gustave Roussy, France
The efficacy of denosumab and zoledronic acid as treatment for prostate cancer ( Dr Karim Fizazi - Institut Gustave Roussy, France )
8 Jul 2010
Circulating tumour cells in breast cancer
Dr Brigitte Rack, Munich University Hospital, Germany
Circulating tumour cells in breast cancer ( Dr Brigitte Rack, Munich University Hospital, Germany )
8 Jul 2010
The influence of zoledronic acid on the treatment of endocrine-responsive early ...
Prof Michael Gnant - Medical University of Vienna, Austria
The influence of zoledronic acid on the treatment of endocrine-responsive early breast cancer ( Prof Michael Gnant - Medical University of Vienna, Austria )
7 Jul 2010
Frontline treatments for lymphomas
Professor Bruce Cheson, Lombardi Comprehensive Cancer Center, Washington DC, USA
Frontline treatments for lymphomas ( Professor Bruce Cheson, Lombardi Comprehensive Cancer Center, Washington DC, USA )
6 Jul 2010
New agent eribulin prolongs survival in metastatic breast cancer
Professor Chris Twelves - St James's Hospital, Leeds, UK
New agent eribulin prolongs survival in metastatic breast cancer ( Professor Chris Twelves - St James's Hospital, Leeds, UK )
30 Jun 2010
Primary end points of clinical trials - overall survival versus progression free...
Prof David Cameron, Prof Patrick Schöffski, Prof Hilary Calvert
Primary end points of clinical trials - overall survival versus progression free survival. ( Prof David Cameron, Prof Patrick Schöffski, Prof Hilary Calvert )
30 Jun 2010
Clinical trial Design: Comparator arms
Prof David Cameron, Dr Christopher M Nutting, Dr Ruth Pettengell, Professor Jace...
Clinical trial Design: Comparator arms ( Prof David Cameron, Dr Christopher M Nutting, Dr Ruth Pettengell, Professor Jacek Jassem )
30 Jun 2010
Results of the multiple myeloma study comparing zoledronic acid to clodronate
Prof Gareth Morgan - Institute of Cancer Research, Sutton, UK
Results of the multiple myeloma study comparing zoledronic acid to clodronate ( Prof Gareth Morgan - Institute of Cancer Research, Sutton, UK )
25 Jun 2010
Conatumumab or AMG 479 as treatment for pancreatic cancer
Prof Hedy Kindler - University of Chicago, USA
Conatumumab or AMG 479 as treatment for pancreatic cancer ( Prof Hedy Kindler - University of Chicago, USA )
25 Jun 2010
NKTR-102: a new drug for treating platinum-resistant or refractory ovarian cance...
Professor Ignace Vergote - Catholic University of Leuven, Belgium
NKTR-102: a new drug for treating platinum-resistant or refractory ovarian cancer ( Professor Ignace Vergote - Catholic University of Leuven, Belgium )
25 Jun 2010
The efficacy of bendamustine and rituximab in the treatment of indolent lymphoma...
Dr Mathias Rummel - University Hospital, Giessen, Germany
The efficacy of bendamustine and rituximab in the treatment of indolent lymphoma diseases ( Dr Mathias Rummel - University Hospital, Giessen, Germany )
25 Jun 2010
Breast cancers that spread to the liver may change biology, impacting treatment ...
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
Breast cancers that spread to the liver may change biology, impacting treatment effectiveness ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
11 Jun 2010
Roundup of the 2010 ASCO conference
Prof Gordon McVie - European Institute of Oncology, Milan
Roundup of the 2010 ASCO conference ( Prof Gordon McVie - European Institute of Oncology, Milan )
11 Jun 2010
Antibody drug ipilimumab improves long-term survival in previously treated advan...
Dr Steven O'Day - The Angeles Clinic and Research Institute, Santa Monica, Calif...
Antibody drug ipilimumab improves long-term survival in previously treated advanced melanoma ( Dr Steven O'Day - The Angeles Clinic and Research Institute, Santa Monica, California )
11 Jun 2010
New agent, eribulin, derived from marine sponge, increases survival among women ...
Prof Christopher Twelves - Leeds Institute of Molecular Medicine and St. James's...
New agent, eribulin, derived from marine sponge, increases survival among women with metastatic breast cancer ( Prof Christopher Twelves - Leeds Institute of Molecular Medicine and St. James's Institute of Oncology, Leeds, UK )
11 Jun 2010
ALK inhibitor shows high response rate in patients with advanced NSCLC harboring...
Prof Yung-Jue Bang - Seoul National University College of Medicine, Seoul, Korea
ALK inhibitor shows high response rate in patients with advanced NSCLC harboring a specific gene alteration ( Prof Yung-Jue Bang - Seoul National University College of Medicine, Seoul, Korea )
11 Jun 2010